What are the definition, typical presenting symptoms, diagnostic criteria, recommended GP management, and red‑flag features for referral of bronchiectasis according to Australian guidelines?

Bronchiectasis: Concise GP Management Guide

Definition

Bronchiectasis is a chronic inflammatory lung disease defined by permanent, irreversible bronchial dilatation on chest CT scan, accompanied by characteristic clinical symptoms including chronic cough, sputum production, and recurrent respiratory infections 1.

Chief Complaints

Patients typically present with:

• Chronic productive cough (most common)
• Daily sputum production (often purulent)
• Recurrent chest infections
• Dyspnoea (breathlessness)
• Fatigue
• Haemoptysis (in some cases)
• Chest pain

1, 2, 3

Diagnostic Criteria

Diagnosis requires BOTH radiological AND clinical features 4:

Radiological Confirmation (Essential):

• High-resolution chest CT scan showing bronchial dilatation (bronchus wider than accompanying artery - the "signet ring sign")
• Use age-appropriate protocols in younger patients 2

Clinical Features (Must be present):

• Chronic cough with sputum production
• Recurrent respiratory infections
• Compatible symptoms as above

Baseline Investigations Panel 2, 5:

• Sputum culture (bacterial and mycobacterial - essential)
• Full blood count
• Serum immunoglobulins (IgG, IgA, IgM, IgE)
• Aspergillus serology (for allergic bronchopulmonary aspergillosis)
• Spirometry
• Consider: autoimmune screen if clinically indicated

GP Management Approach

Core Non-Pharmacological Management:

1. Airway Clearance Techniques (ACTs) - STRONG recommendation 1

   • Refer to respiratory physiotherapist for individualized teaching
   • Should be performed regularly, especially if chronic productive cough present
   • This is the cornerstone of management 5

2. Pulmonary Rehabilitation - STRONG recommendation 1

   • Refer all patients with impaired exercise capacity
   • Improves quality of life and reduces exacerbations

3. Lifestyle Modifications 2:

   • Smoking cessation (mandatory)
   • Regular exercise
   • Optimize nutrition
   • Avoid air pollutants

4. Vaccinations 5:

   • Annual influenza vaccination
   • Pneumococcal vaccination per national schedule

Pharmacological Management:

What TO Use:

• Acute exacerbations: 14-day antibiotic courses based on sputum culture results 2
• Long-term macrolides (e.g., azithromycin): STRONG recommendation for patients with ≥3 exacerbations per year 1
• Mucoactive agents: Conditional recommendation in selected patients with difficult-to-clear secretions 1

What NOT to Routinely Use:

• Inhaled corticosteroids: Conditional recommendation AGAINST routine use 1, 5
  • Only use if concomitant asthma or COPD present
  • Currently overused in Australian practice (48% of patients) 6
• Long-term oral non-macrolide antibiotics: Not recommended 1

Exacerbation Management 2:

• 14-day antibiotic course (longer than typical respiratory infections)
• Base selection on previous sputum culture results
• Consider local antibiotic resistance patterns
• Intensify airway clearance
• Hospitalize if: severe exacerbation, not responding to outpatient therapy, or significant comorbidities

Pseudomonas aeruginosa Management:

• Eradicate when newly detected 2
• Long-term inhaled antibiotics: STRONG recommendation for chronic P. aeruginosa infection in high-risk patients (≥3 exacerbations/year) 1

Red Flags for Specialist Referral

Refer urgently to respiratory physician if:

1. Diagnostic uncertainty or complex presentation
2. Severe disease at presentation:
   • FEV1 <50% predicted
   • Extensive radiological disease
   • Frequent exacerbations (≥3 per year)
3. Pseudomonas aeruginosa or non-tuberculous mycobacteria isolated in sputum 2
4. Massive haemoptysis (>200mL in 24 hours)
5. Suspected underlying conditions requiring specialist management:
   • Primary ciliary dyskinesia
   • Immunodeficiency
   • Allergic bronchopulmonary aspergillosis
   • Connective tissue disease
6. Progressive decline despite optimal management:
   • Declining lung function
   • Increasing exacerbation frequency
   • Deteriorating quality of life
7. Consideration for long-term antibiotic therapy (macrolides or inhaled antibiotics)
8. Surgical assessment needed (localized disease amenable to resection)

2, 3, 5

Common Pitfalls to Avoid

• Underdiagnosis: Bronchiectasis often coexists with asthma and COPD - maintain high index of suspicion in patients with chronic productive cough 2, 3
• Inadequate sputum sampling: Only 59% of Australian patients have bacterial cultures, 29% have mycobacterial cultures 6 - this is essential for management
• Overuse of inhaled corticosteroids: These are NOT routinely indicated unless concomitant asthma/COPD 1, 6
• Short antibiotic courses for exacerbations: Use 14 days, not the typical 5-7 days 2
• Neglecting airway clearance: This remains the cornerstone - ensure physiotherapy referral 1, 5
• Missing pulmonary rehabilitation: Only 22% of eligible Australian patients attend despite 67% being indicated 6

Ongoing Monitoring

• 6-monthly reviews minimum 2
• Monitor for complications and comorbidities
• Assess exacerbation frequency
• Review adherence to airway clearance
• Repeat sputum cultures regularly
• Monitor lung function annually

2, 3